A recent report from the US president’s executive office on reducing drug prices makes reassuring reading for innovators concerned about the future of pharmaceutical patents under the Trump administration. In contrast to comments previously made by the president and his new health secretary Alex Azar, the paper robustly defends innovators’ IP rights, while recommending regulatory and insurance reforms, as well as a clamp down on foreign “free-riding”, to lower medical costs.

Want to read more?

Register to access two of our subscriber-only articles per month

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts

Already registered? Log in

What our customers are saying

Well-written, in-depth coverage that is not found on this side of the ‘pond’. Thank you for that.

Frederic M Wilf
Technology, intellectual property and business lawyer
Wilftek LLC


Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.

Why subscribe?